Navigation Links
U.S. PTO Reexamining Lumenis Patents
Date:3/26/2008

Lumenis Patent Litigation with Alma Lasers Stayed

CAESAREA, Israel, March 26 /PRNewswire/ -- Alma Lasers Ltd., a global leader in aesthetic laser, light-based, and radiofrequency systems, announces important developments in its patent dispute with Lumenis Ltd., which is being litigated in the United States District Court in Chicago, IL. Alma reports that: (1) the U.S. Patent and Trademark Office in Alexandria VA ("PTO") has decided to reexamine all seven of Lumenis's patents that are at issue in the litigation, and (2) the Court has stayed the litigation, pending reexamination of the patents.

In December 2007, Alma submitted 22 prior art references to the PTO for consideration with respect to the seven Lumenis patents. Subsequently, the PTO found a "substantial new question of patentability" with respect to each of the seven patents, and commenced reexamination of them. With respect to one of those patents, the PTO, on February 8, 2008, issued an Office Action rejecting 26 claims of the patent as obvious or anticipated by the prior art. On February 21, 2008, the District Court ordered the litigation stayed pending the PTO's reexamination.

Lumenis initiated the Chicago litigation by filing suit against Alma Lasers on June 28, 2007. On January 25, 2008, Alma filed counterclaims and, among other things, asked the Court to declare six of the seven Lumenis patents unenforceable due to inequitable conduct in procuring those patents. Alma alleged that, when applying for those six patents, the applicants breached their duty of candor, good faith and honesty to the PTO and engaged in inequitable conduct by making false representations to the PTO and by failing to disclose material prior art to the PTO. Lumenis denied the allegations.

"Alma Lasers continues to build momentum in the marketplace due to its innovation, value and excellent customer service," stated Howard Kelly, CEO of Alma Lasers. "It is unfortunate that certain compet
'/>"/>

SOURCE Alma Lasers Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lumenis Ltd. Announces Appointment of Corporate Vice President, Business Development in support of the companys long-term growth strategy
2. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
3. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
4. iCAD, Inc. Awarded Two Additional Patents for Its Computer-Aided Detection Technology
5. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
6. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
7. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Research and Markets ... "Global DNA Diagnostics Market (Product types, Application, Technology, ... Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, ... report to their offering. This ... techniques, end users and Geography) Global Size, Industry ...
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... October 22, 2014 According to ... by Service Type (Consulting, Integration, Deployment & Support), ... Deployment Model (Public, Private, Others (Hybrid & Community)) ... defines and segments the Cloud Professional Services Market ... forecasting of revenues. It also identifies the drivers ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... The organizers of Pharma,ChemOutsourcing Conference & Exhibition ... and biotech company speakers who,will gather in ... around the,exploding chemical outsourcing activities reshaping R ... industry, reports Apaporis LLC. The,conference program may ...
... 2 ev3 Inc. (Nasdaq:,EVVV), a global endovascular device ... of 2008 and its revised financial,guidance for 2008., ... in the,first quarter of 2008 representing a 65% increase ... 10% increase over the fourth quarter of 2007. The,increase ...
... The timing of the live teleconference should have read: "9:00 am ... follows: Resverlogix Notice ... ... pleased to announce that it will host a live,teleconference on May 8, 2008 at ...
Cached Biology Technology:Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 2ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 3ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 4ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 5ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 6ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 7ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 8ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 9ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 10ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 11ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance 12/C O R R E C T I O N from Source -- Resverlogix Corp./ 2
(Date:10/22/2014)... Calif. , Oct. 20, 2014 The ... United States Air Force Research Laboratory (AFRL), has chosen ... Medicine (AzCIM) at the University of Arizona College of ... research funding.  The AzCIM project,s goal is to assess ... to collect different volumes of sweat under a variety ...
(Date:10/22/2014)... Mass., Oct. 21, 2014 Aware, Inc. (NASDAQ: ... services, today reported financial results for its third quarter ended ... of 2014 was $6.0 million, an increase of 40% compared ... income in the third quarter of 2014 was $4.1 million ... Higher operating income in the current three month period was ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2
... Ill. (March 28, 2011)Deep vein thrombosis, or DVT: it,s ... long plane ride. The Society of Interventional Radiology wants ... serious condition, which can lead to post-thrombotic syndrome, pulmonary ... "Individuals and their doctors need to be ...
... of Utah scientists used invisible infrared light to make ... signals to the brain. The discovery someday might improve ... restore vision, maintain balance and treat movement disorders like ... with optical infrared pulses instead of electrical pulses," which ...
... Researchers have described how the most common gene ... of cancer development and how it can cooperate with ... leukaemia. The researchers suggest that three critical steps ... ones, each subverting a different cellular process. By charting ...
Cached Biology News:Interventional radiologists take lead on reducing disability from dangerous blood clots 2Interventional radiologists take lead on reducing disability from dangerous blood clots 3Interventional radiologists take lead on reducing disability from dangerous blood clots 4Will we hear the light? 2Will we hear the light? 3Will we hear the light? 4Will we hear the light? 5The gene processes that drive acute myeloid leukaemia 2The gene processes that drive acute myeloid leukaemia 3
G-Protein Coupled Receptor Assay, For 500 assays. SPA. Category: Drug Screening & Cellular Assays, Assays ....
... 9 oligodeoxynucleotides are random ... at the 5' end ... Fluor dyes and they ... microarray spot morphology, hybridization ...
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Mycoplasma tested...
Biology Products: